

# Edward M Sellers

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2715163/edward-m-sellers-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225 papers	13,663 citations	65 h-index	108 g-index
230 ext. papers	14,749 ext. citations	6.8 avg, IF	5.98 L-index

#	Paper	IF	Citations
225	5-HT and 5-HT receptors as potential targets for the treatment of nicotine use and dependence. <i>Progress in Brain Research</i> , <b>2021</b> , 259, 229-263	2.9	2
224	Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 640241	5.6	6
223	Identification of Optimal Measures of Human Abuse Potential: A Post Hoc Assessment of 19 Studies. <i>Journal of Clinical Psychopharmacology</i> , <b>2020</b> , 40, 568-578	1.7	0
222	Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study. <i>Journal of Clinical Pharmacology</i> , <b>2020</b> , 60, 495-504	2.9	14
221	Categorization of Abuse Potential-Related Adverse Events. <i>Clinical Pharmacology in Drug Development</i> , <b>2018</b> , 7, 569-574	2.3	1
220	Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 561-564	6.1	13
219	Studies with psychedelic drugs in human volunteers. <i>Neuropharmacology</i> , <b>2018</b> , 142, 116-134	5.5	15
218	Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2: Optimizing the Design of Human Abuse Potential Studies. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 113-118	1.7	2
217	Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 1: Regulatory Context and Risk Management. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 11-18	1.7	1
216	Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. <i>Epilepsy and Behavior</i> , <b>2018</b> , 88, 162-171	3.2	64
215	A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. <i>Journal of Psychopharmacology</i> , <b>2018</b> , 32, 1351-1361	4.6	86
214	Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 675-683	1.7	4
213	Deconstructing Designer Drugs. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 101, 167-169	6.1	3
212	Oral Human Abuse Potential of Oxycodone DETERx (Xtampza ER). <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57, 500-512	2.9	21
211	Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 314-23	1.7	15
210	Claudio A. Naranjo, MD (1945-2014). <i>Clinical Pharmacology and Therapeutics</i> , <b>2015</b> , 97, 14-5	6.1	
209	Use of Remifentanyl in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent $\mu$ -Receptor Antagonist. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 242-9	1.7	41

208	Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 396-405	1.7	34
207	Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory. <i>Journal of Molecular Neuroscience</i> , <b>2014</b> , 54, 59-70	3.3	12
206	Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. <i>CNS Drugs</i> , <b>2014</b> , 28, 361-72	6.7	10
205	Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 468-77	2.9	43
204	Human abuse liability evaluation of CNS stimulant drugs. <i>Neuropharmacology</i> , <b>2014</b> , 87, 81-90	5.5	21
203	Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. <i>Neuropsychiatric Disease and Treatment</i> , <b>2014</b> , 10, 1161-74	3.1	23
202	The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. <i>Pharmaceutical Medicine</i> , <b>2014</b> , 28, 317-327	2.3	4
201	Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. <i>Journal of Opioid Management</i> , <b>2014</b> , 10, 119-34	0.8	19
200	From obesity to substance abuse: therapeutic opportunities for 5-HT <sub>2C</sub> receptor agonists. <i>Trends in Pharmacological Sciences</i> , <b>2013</b> , 34, 560-70	13.2	77
199	Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 808-16	4.6	29
198	A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. <i>Clinical Pharmacology in Drug Development</i> , <b>2013</b> , 2, 285-94	2.3	19
197	Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum. <i>Journal of Pain Research</i> , <b>2013</b> , 6, 791-801	2.9	15
196	A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, e1-15	3.2	6
195	Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, 157-69	3.2	11
194	Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. <i>Pain</i> , <b>2012</b> , 153, 2315-2324	8	41
193	Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. <i>Clinical Therapeutics</i> , <b>2012</b> , 34, 1170-81	3.5	15
192	Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 492-502	1.7	12
191	Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta) tablets in nondependent recreational opioid users. <i>Journal of Opioid Management</i> , <b>2012</b> , 8, 315-27	0.8	8

190	A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, e1-e15	3.2	5
189	A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. <i>Human Psychopharmacology</i> , <b>2011</b> , 26, 224-36	2.3	47
188	Effects of low-dose opioids on cognitive dysfunction. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4342-3; author reply 4343-4	2.2	28
187	Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. <i>Journal of Opioid Management</i> , <b>2011</b> , 7, 179-92 <sup>8</sup>	2.8	22
186	New CYP2A6 gene deletion and conversion variants in a population of Black African descent. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 189-98	2.6	30
185	The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. <i>Drug and Alcohol Dependence</i> , <b>2010</b> , 112, 173-7	4.9	13
184	Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. <i>Epilepsy and Behavior</i> , <b>2010</b> , 18, 366-73	3.2	35
183	Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. <i>Journal of Clinical Psychopharmacology</i> , <b>2010</b> , 30, 25-33	1.7	34
182	Effect of metabolic blockade on the psychoactive effects of dextromethorphan. <i>Human Psychopharmacology</i> , <b>2010</b> , 25, 71-9	2.3	18
181	Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. <i>Pain Physician</i> , <b>2010</b> , 13, 561-73	1.8	8
180	A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 274-82	3.5	35
179	Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report. <i>Drug and Alcohol Dependence</i> , <b>2009</b> , 105 Suppl 1, S65-71	4.9	16
178	Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. <i>Clinical Drug Investigation</i> , <b>2009</b> , 29, 777-90	3.2	51
177	Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. <i>Nicotine and Tobacco Research</i> , <b>2008</b> , 10, 1319-25	4.9	6
176	Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. <i>Human Mutation</i> , <b>2008</b> , 29, 679-88	4.7	62
175	Pharmacotherapy of Alcohol Dependence: Improving Translation from the Bench to the Clinic <b>2008</b> , 91-178		1
174	Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. <i>Carcinogenesis</i> , <b>2007</b> , 28, 2139-42	4.6	28
173	Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. <i>Journal of Clinical Pharmacology</i> , <b>2007</b> , 47, 1476-88	2.9	44

172	Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 459-67	1.7	58
171	Challenges in the development of prescription opioid abuse-deterrent formulations. <i>Clinical Journal of Pain</i> , <b>2007</b> , 23, 648-60	3.5	116
170	Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. <i>Drug and Alcohol Dependence</i> , <b>2007</b> , 89, 24-33	4.9	61
169	The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. <i>Journal of Clinical Pharmacology</i> , <b>2007</b> , 47, 604-12	2.9	16
168	Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 481-4	2.8	21
167	Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. <i>Psychopharmacology</i> , <b>2006</b> , 186, 425-33	4.7	93
166	CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 1812-9	4	50
165	Research design strategies to evaluate the impact of formulations on abuse liability. <i>Drug and Alcohol Dependence</i> , <b>2006</b> , 83 Suppl 1, S52-62	4.9	50
164	Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 345-52	2.9	10
163	Relative abuse potential of opioid formulations in Canada: a structured field study. <i>Journal of Opioid Management</i> , <b>2006</b> , 2, 219-27	0.8	16
162	Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. <i>Journal of Clinical Pharmacology</i> , <b>2005</b> , 45, 1413-21	2.9	40
161	Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. <i>Pharmacogenetics and Genomics</i> , <b>2005</b> , 15, 189-92	1.9	35
160	Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 145-58	6.1	199
159	Nicotine physical dependence and tolerance in the mouse following chronic oral administration. <i>Psychopharmacology</i> , <b>2005</b> , 178, 183-92	4.7	72
158	3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. <i>Gynecological Endocrinology</i> , <b>2005</b> , 21, 268-79	2.4	80
157	Mood changes during pregnancy and the postpartum period: development of a biopsychosocial model. <i>Acta Psychiatrica Scandinavica</i> , <b>2004</b> , 109, 457-66	6.5	110
156	EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. <i>Psychopharmacology</i> , <b>2004</b> , 175, 382-8	4.7	14
155	Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 1132-42	2.9	73

154	Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 966-73	2.9	5
153	Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 615-26		244
152	Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. <i>Drug Metabolism and Disposition</i> , <b>2003</b> , 31, 768-72	4	46
151	CYP2E1*1D regulatory polymorphism. <i>Pharmacogenetics and Genomics</i> , <b>2003</b> , 13, 321-328		46
150	. <i>Journal of Clinical Psychopharmacology</i> , <b>2003</b> , 23, 269-280	1.7	7
149	Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. <i>Journal of Clinical Psychopharmacology</i> , <b>2003</b> , 23, 269-80	1.7	20
148	Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. <i>Intensive Care Medicine</i> , <b>2003</b> , 29, 2230-2238	14.5	100
147	Measurement issues in postpartum depression part 1: anxiety as a feature of postpartum depression. <i>Archives of Women's Mental Health</i> , <b>2003</b> , 6, 51-7	5	205
146	Decreasing smoking behaviour and risk through CYP2A6 inhibition. <i>Drug Discovery Today</i> , <b>2003</b> , 8, 487-93	3.8	66
145	Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 74, 437-47	6.1	112
144	Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2003</b> , 306, 941-7	4.7	40
143	Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. <i>Molecular Pharmacology</i> , <b>2003</b> , 63, 96-104	4.3	56
142	The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. <i>Nicotine and Tobacco Research</i> , <b>2003</b> , 5, 891-9	4.9	51
141	CYP2A6 genetic variation and potential consequences. <i>Advanced Drug Delivery Reviews</i> , <b>2002</b> , 54, 1245-58	5.5	107
140	Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. <i>Biochemical Pharmacology</i> , <b>2002</b> , 63, 2111-9	6	52
139	Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 192-9	6.1	30
138	Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. <i>Journal of Women's Health and Gender-Based Medicine</i> , <b>2002</b> , 11, 147-53		48
137	Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. <i>Drug Metabolism and Disposition</i> , <b>2002</b> , 30, 663-9	4	16



136	The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. <i>Pharmacogenomics</i> , <b>2002</b> , 3, 185-99	2.6	44
135	Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. <i>Archives of General Psychiatry</i> , <b>2002</b> , 59, 851-8		282
134	Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 326-9	1.7	21
133	Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 163-71	3.2	106
132	Designer drugs that are potent inhibitors of CYP2D6. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 330-2	1.7	11
131	Inhibition of cytochromes P450 by antifungal imidazole derivatives. <i>Drug Metabolism and Disposition</i> , <b>2002</b> , 30, 314-8	4	202
130	An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 290, 318-24	3.4	114
129	Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. <i>Biochemical Pharmacology</i> , <b>2001</b> , 62, 1025-36	6	31
128	Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2001</b> , 79, 841-847	2.4	52
127	Use of hair analysis for confirmation of self-reported cocaine use in users with negative urine tests. <i>Journal of Toxicology: Clinical Toxicology</i> , <b>2001</b> , 39, 361-6		20
126	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. <i>Pharmacogenetics and Genomics</i> , <b>2001</b> , 11, 477-87		87
125	Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. <i>Pharmacogenetics and Genomics</i> , <b>2001</b> , 11, 85-94		44
124	Cognitive toxicity of drugs used in the elderly. <i>Dialogues in Clinical Neuroscience</i> , <b>2001</b> , 3, 181-90	5.7	6
123	Mimicking gene defects to treat drug dependence. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 909, 233-46	6.5	34
122	Efficacy of Dexfenfluramine in the Treatment of Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2000</b> , 24, 1534-1541	3.7	4
121	Inhibition of cytochrome P450 2A6 increases nicotine® oral bioavailability and decreases smoking. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 35-43	6.1	126
120	Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. <i>Molecular Pharmacology</i> , <b>2000</b> , 58, 747-55	4.3	203
119	Lack of interaction of buprenorphine with flunitrazepam metabolism. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 1164-6	11.9	32

118	Long-term benzodiazepine therapy does not result in brain abnormalities. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 2-6	1.7	15
117	Cytochrome P450 2D6 and treatment of codeine dependence. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 43-5	1.7	23
116	Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 435-44	1.7	42
115	Comparative abuse liability of intravenously administered remifentanyl and fentanyl. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 597-606	1.7	26
114	A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. <i>Journal of Clinical Psychopharmacology</i> , <b>2000</b> , 20, 628-35	1.7	14
113	Neurosteroids: A New Regulatory Function in the Nervous System. <i>Behavioural Neurology</i> , <b>1999</b> , 11, 261-262	1.7	3
112	A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. <i>Nicotine and Tobacco Research</i> , <b>1999</b> , 1 Suppl 2, S63-7; discussion S69-70	4.9	29
111	Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. <i>Drug and Alcohol Dependence</i> , <b>1999</b> , 54, 239-49	4.9	21
110	Characteristics of dependent and nondependent regular users of codeine. <i>Journal of Clinical Psychopharmacology</i> , <b>1999</b> , 19, 367-72	1.7	63
109	Long-term codeine use is associated with depressive symptoms. <i>Journal of Clinical Psychopharmacology</i> , <b>1999</b> , 19, 373-6	1.7	38
108	Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. <i>Journal of Clinical Psychopharmacology</i> , <b>1999</b> , 19, 472-5	1.7	25
107	Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. <i>Clinical Pharmacology and Therapeutics</i> , <b>1998</b> , 64, 378-83	6.1	36
106	Nicotine metabolism defect reduces smoking. <i>Nature</i> , <b>1998</b> , 393, 750	50.4	289
105	NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. <i>Pharmacogenetics and Genomics</i> , <b>1998</b> , 8, 305-13		73
104	Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. <i>Pharmacogenetics and Genomics</i> , <b>1998</b> , 8, 325-33		80
103	The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 55-61	1.7	25
102	A controlled trial of ondansetron, a 5-HT <sub>3</sub> antagonist, in benzodiazepine discontinuation. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 121-31	1.7	26
101	Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 198-207	1.7	19



100	Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 332-7	1.7	40
99	CYP2D6 phenotype and genotype in a Canadian Native Indian population. <i>Pharmacogenetics and Genomics</i> , <b>1997</b> , 7, 145-8		19
98	Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. <i>Pharmacogenetics and Genomics</i> , <b>1997</b> , 7, 375-9		111
97	Interactions of amphetamine analogs with human liver CYP2D6. <i>Biochemical Pharmacology</i> , <b>1997</b> , 53, 1605-12	6	139
96	Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1997</b> , 22, 295-304	2.7	23
95	An improved HPLC method for analysis of methamphetamine and its metabolites in plasma. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1997</b> , 22, 427-32	2.7	9
94	Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. <i>Clinical Pharmacology and Therapeutics</i> , <b>1997</b> , 62, 334-47	6.1	76
93	CYP2D6 inhibition in patients treated with sertraline. <i>Journal of Clinical Psychopharmacology</i> , <b>1997</b> , 17, 102-6	1.7	40
92	Multiple drug use and psychiatric comorbidity in patients admitted to the hospital with severe benzodiazepine dependence. <i>Journal of Clinical Psychopharmacology</i> , <b>1996</b> , 16, 51-7	1.7	43
91	Effect of the 5-HT <sub>3</sub> antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. <i>Psychopharmacology</i> , <b>1995</b> , 117, 479-85	4.7	71
90	Treatment of the Acute Alcohol Withdrawal State: A Comparison of Four Drugs. <i>Alcohol Health and Research World</i> , <b>1995</b> , 19, 34-35		
89	Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. <i>Journal of Clinical Psychopharmacology</i> , <b>1995</b> , 15, 117-24	1.7	34
88	Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. <i>Journal of Clinical Psychopharmacology</i> , <b>1995</b> , 15, 263-9	1.7	93
87	Low doses of the 5-HT <sub>1A</sub> agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake. <i>Psychopharmacology</i> , <b>1994</b> , 115, 173-9	4.7	53
86	Influence of 5-HT <sub>3</sub> receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. <i>Psychopharmacology</i> , <b>1994</b> , 114, 611-9	4.7	40
85	Effect of dexfenfluramine on saccharin drinking: behavioural and pharmacological studies. <i>Pharmacology Biochemistry and Behavior</i> , <b>1994</b> , 47, 307-15	3.9	4
84	Antagonist-precipitated opioid withdrawal in rats: evidence for dissociations between physical and motivational signs. <i>Pharmacology Biochemistry and Behavior</i> , <b>1994</b> , 48, 1-8	3.9	74
83	Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 55, 451-63	6.1	44

82	Clinical efficacy of the 5-HT <sub>3</sub> antagonist ondansetron in alcohol abuse and dependence. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1994</b> , 18, 879-85	3.7	152
81	The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol. <i>Brain Research</i> , <b>1994</b> , 640, 246-54	3.7	24
80	CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. <i>Clinical Pharmacology and Therapeutics</i> , <b>1993</b> , 54, 463-72	6.1	144
79	Inhibition by fluoxetine of cytochrome P450 2D6 activity. <i>Clinical Pharmacology and Therapeutics</i> , <b>1993</b> , 53, 401-9	6.1	228
78	Preliminary findings with the indirect 5-HT agonist dexfenfluramine on heroin discrimination and self-administration in rats. <i>Pharmacology Biochemistry and Behavior</i> , <b>1993</b> , 45, 963-6	3.9	15
77	Effect of 5-HT <sub>3</sub> receptor antagonists on the discriminative stimulus properties of morphine in rats. <i>Psychopharmacology</i> , <b>1993</b> , 112, 111-5	4.7	22
76	Characteristics of Long-term Alprazolam Users in the Community. <i>Journal of Clinical Psychopharmacology</i> , <b>1992</b> , 12, 316-321	1.7	17
75	Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists. <i>Brain Research</i> , <b>1992</b> , 572, 208-15	3.7	57
74	The NMDA antagonist dizocilpine (MK801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. <i>Life Sciences</i> , <b>1992</b> , 50, PL167-72	6.8	60
73	5-HT and alcohol abuse. <i>Trends in Pharmacological Sciences</i> , <b>1992</b> , 13, 69-75	13.2	244
72	Effect of drugs influencing 5-HT function on ethanol drinking and feeding behaviour in rats: studies using a drinkometer system. <i>Neuroscience and Biobehavioral Reviews</i> , <b>1992</b> , 16, 535-52	9	84
71	Effect of the 5-HT <sub>3</sub> receptor antagonists, MDL72222 and ondansetron on morphine place conditioning. <i>Psychopharmacology</i> , <b>1992</b> , 106, 315-20	4.7	79
70	Characterization of DSM-III-R criteria for uncomplicated alcohol withdrawal provides an empirical basis for DSM-IV. <i>Archives of General Psychiatry</i> , <b>1991</b> , 48, 442-7		47
69	Drug metabolism and interactions in abuse liability assessment. <i>Addiction</i> , <b>1991</b> , 86, 1607-14	4.6	4
68	Anxiolytics and sedative/hypnotics dependence. <i>Addiction</i> , <b>1991</b> , 86, 1647-52	4.6	24
67	Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 50, 96-106	6.1	16
66	Pharmacotherapy of alcohol and drug problems. <i>Drug and Alcohol Review</i> , <b>1991</b> , 10, 215-24	3.2	0
65	Effects of 5-HT <sub>3</sub> receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. <i>Psychopharmacology</i> , <b>1991</b> , 105, 322-8	4.7	47

64	Blockade of morphine place conditioning by the CCKA receptor antagonist devazepide. <i>European Journal of Pharmacology</i> , <b>1991</b> , 197, 229-30	5.3	15
63	Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 47, 490-8	6.1	187
62	Ethanol interactions with serotonin uptake selective and non-selective antidepressants: Fluoxetine and amitriptyline. <i>Human Psychopharmacology</i> , <b>1989</b> , 4, 113-120	2.3	14
61	Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). <i>Addiction</i> , <b>1989</b> , 84, 1353-7	4.6	1148
60	Differential effects of vicaline on alcohol intake and other consummatory behaviors. <i>Clinical Pharmacology and Therapeutics</i> , <b>1989</b> , 46, 301-9	6.1	73
59	Clinical pharmacokinetics of non-opiate abused drugs. <i>Clinical Pharmacokinetics</i> , <b>1989</b> , 16, 1-26	6.2	69
58	A Clinical Scale to Assess Benzodiazepine Withdrawal. <i>Journal of Clinical Psychopharmacology</i> , <b>1989</b> , 9, 412-416	1.7	61
57	Serotonin Uptake Inhibitors Attenuate Ethanol Intake in Humans. <i>Australian Drug and Alcohol Review</i> , <b>1988</b> , 7, 109-112		3
56	A Reply to Dr Andrew Johns. <i>Addiction</i> , <b>1988</b> , 83, 1116-1117	4.6	
55	Defining the true therapeutics and clinical pharmacology curriculum in a Canadian medical school: implications for change. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 44, 629-33	6.1	8
54	Compliance among heavy alcohol users in clinical drug trials. <i>Journal of Substance Abuse</i> , <b>1988</b> , 1, 183-94		11
53	Drug deprivation and reinforcement by diazepam in a dependent population. <i>Psychopharmacology</i> , <b>1987</b> , 91, 154-60	4.7	24
52	The serotonin uptake inhibitor citalopram attenuates ethanol intake. <i>Clinical Pharmacology and Therapeutics</i> , <b>1987</b> , 41, 266-74	6.1	207
51	Patterns of benzodiazepine abuse and dependence. <i>Addiction</i> , <b>1986</b> , 81, 87-94	4.6	72
50	Withdrawal reaction after long-term therapeutic use of benzodiazepines. <i>New England Journal of Medicine</i> , <b>1986</b> , 315, 854-9	59.2	310
49	Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective. <i>Clinical Pharmacokinetics</i> , <b>1986</b> , 11, 144-53	6.2	71
48	Treatment of the barbiturate abstinence syndrome*. <i>Medical Journal of Australia</i> , <b>1986</b> , 145, 456-458	4	10
47	Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. <i>Recent Developments in Alcoholism: an Official Publication of the American Medical Society on Alcoholism, and the Research Society on Alcoholism, and the National Council on Alcoholism</i> , <b>1986</b> , 4, 265-81		35

46	Benzodiazepines as Drugs of Abuse and Dependence <b>1986</b> , 53-126		8
45	Triazolam and ethanol interaction: kinetic and dynamic consequences. <i>Clinical Pharmacology and Therapeutics</i> , <b>1985</b> , 37, 558-62	6.1	28
44	Acute kinetic and dynamic interactions of zimelidine with ethanol. <i>Clinical Pharmacology and Therapeutics</i> , <b>1984</b> , 36, 654-60	6.1	25
43	Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1984</b> , 35, 374-81	6.1	204
42	Nonpharmacologic intervention in acute alcohol withdrawal. <i>Clinical Pharmacology and Therapeutics</i> , <b>1983</b> , 34, 214-9	6.1	70
41	In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. <i>British Journal of Anaesthesia</i> , <b>1983</b> , 55, 985-9	5.4	69
40	Objective determination of benzodiazepine use and abuse in alcoholics. <i>Addiction</i> , <b>1983</b> , 78, 429-35	4.6	50
39	Importance of protein binding for the interpretation of serum or plasma drug concentrations. <i>Journal of Clinical Pharmacology</i> , <b>1982</b> , 22, 259-63	2.9	101
38	Drug-plasma protein binding in Kutchin Athapaskan indians. <i>Clinical Pharmacology and Therapeutics</i> , <b>1982</b> , 32, 436-41	6.1	2
37	Difficulties in assessing adverse drug reactions in clinical trials. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1982</b> , 6, 651-7	5.5	17
36	Age- and sex-related differences in patterns of drug overdose and abuse. <i>Social Science &amp; Medicine Part E, Medical Psychology</i> , <b>1981</b> , 15, 275-82		3
35	Clinical detection and assessment of drug induced neurotoxicity. <i>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</i> , <b>1981</b> , 5, 427-34		6
34	Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. <i>Journal of Clinical Psychopharmacology</i> , <b>1981</b> , 1, 382-89	1.7	163
33	Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique. <i>Clinical Pharmacology and Therapeutics</i> , <b>1981</b> , 30, 71-6	6.1	49
32	Phencyclidine ingestion: drug abuse and psychosis. <i>Substance Use and Misuse</i> , <b>1981</b> , 16, 749-58		9
31	Drug therapy: Drugs to decrease alcohol consumption. <i>New England Journal of Medicine</i> , <b>1981</b> , 305, 1255-62	5.9	101
30	The nature and etiology of normal and alcohol withdrawal tremor. <i>IEEE Transactions on Biomedical Engineering</i> , <b>1979</b> , 26, 3-10	5	3
29	Intravascular factors affecting diazepam binding to human serum albumin. <i>Biochemical Pharmacology</i> , <b>1979</b> , 28, 3265-70	6	24

28	Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: a kinetic approach. <i>Clinical Pharmacology and Therapeutics</i> , <b>1979</b> , 26, 256-64	6.1	33
27	Chlordiazepoxide and oxazepam disposition in cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , <b>1979</b> , 26, 240-6	6.1	48
26	Age- and gender-related differences in diazepam pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , <b>1979</b> , 19, 15-9	2.9	71
25	Clinical pharmacokinetics of chlordiazepoxide. <i>Clinical Pharmacokinetics</i> , <b>1978</b> , 3, 381-94	6.2	47
24	Drug kinetics and alcohol ingestion. <i>Clinical Pharmacokinetics</i> , <b>1978</b> , 3, 440-52	6.2	90
23	Addictive drugs: disposition, tolerance, and dependence interrelationships. <i>Drug Metabolism Reviews</i> , <b>1978</b> , 8, 5-11	7	14
22	Comparative metabolism of chloral hydrate and triclofos. <i>Journal of Clinical Pharmacology</i> , <b>1978</b> , 18, 457-61	2.9	24
21	The ambiguity of adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , <b>1977</b> , 11, 75-8	2.8	109
20	Diazepam actions and plasma concentrations following ethanol ingestion. <i>European Journal of Clinical Pharmacology</i> , <b>1977</b> , 11, 345-9	2.8	69
19	The effect of propranolol on normal physiologic tremor. <i>Electroencephalography and Clinical Neurophysiology</i> , <b>1976</b> , 41, 310-3		14
18	Drug therapy. Binding of drugs to serum albumin (second of two parts). <i>New England Journal of Medicine</i> , <b>1976</b> , 294, 526-31	59.2	176
17	Partial agonist properties and toxicity of oral oxilorphan. <i>Journal of Clinical Pharmacology</i> , <b>1976</b> , 16, 183-7	2.9	0
16	Alcohol intoxication and withdrawal. <i>New England Journal of Medicine</i> , <b>1976</b> , 294, 757-62	59.2	316
15	Binding of drugs to serum albumin (first of two parts). <i>New England Journal of Medicine</i> , <b>1976</b> , 294, 311-6	59.2	333
14	Interaction of warfarin stereoisomers with human albumin. <i>Pharmacological Research Communications</i> , <b>1975</b> , 7, 331-336		38
13	Binding of diazoxide and other benzothiadiazines to human albumin. <i>Biochemical Pharmacology</i> , <b>1974</b> , 23, 553-66	6	30
12	Clinical pharmacology in Canada. <i>Clinical Pharmacology and Therapeutics</i> , <b>1974</b> , 16, 554-64	6.1	
11	Influence of intravenous injection rate on protein binding and vascular activity of diazoxide. <i>Annals of the New York Academy of Sciences</i> , <b>1973</b> , 226, 319-32	6.5	32

10	Survival after massive procainamide ingestion. <i>American Journal of Cardiology</i> , <b>1973</b> , 32, 727-30	3	22
9	Interaction of chloral hydrate and ethanol in man. I. Metabolism. <i>Clinical Pharmacology and Therapeutics</i> , <b>1972</b> , 13, 37-49	6.1	83
8	Interaction of chloral hydrate and ethanol in man. II. Hemodynamics and performance. <i>Clinical Pharmacology and Therapeutics</i> , <b>1972</b> , 13, 50-8	6.1	28
7	Drug Interactions with Coumarin Anticoagulants. <i>New England Journal of Medicine</i> , <b>1971</b> , 285, 487-498	59.2	207
6	Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. <i>Annals of the New York Academy of Sciences</i> , <b>1971</b> , 179, 213-25	6.5	101
5	Drug interactions with coumarin anticoagulants. 2. <i>New England Journal of Medicine</i> , <b>1971</b> , 285, 547-58	59.2	217
4	Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. <i>Clinical Pharmacology and Therapeutics</i> , <b>1970</b> , 11, 524-9	6.1	97
3	Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. <i>New England Journal of Medicine</i> , <b>1970</b> , 283, 827-31	59.2	85
2	Protein binding and vascular activity of diazoxide. <i>New England Journal of Medicine</i> , <b>1969</b> , 281, 1141-5	59.2	90
1	Modifying the Metabolism of Nicotine as a Therapeutic Strategy. <i>Novartis Foundation Symposium</i> , 235-248		